CONMED Corporation (CNMD)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	132,424	131,740	98,593	82,349	64,459	57,972	88,285	-93,738	-80,582	-82,722	-113,924	67,657	62,542	62,238	54,140	13,450	9,517	310	430	33,525
Total stockholders’ equity	US$ in thousands	962,681	932,896	881,832	854,664	834,222	796,205	780,194	752,453	745,545	716,337	672,968	789,546	785,435	755,683	744,499	725,570	709,038	683,141	674,898	701,635
ROE		13.76%	14.12%	11.18%	9.64%	7.73%	7.28%	11.32%	-12.46%	-10.81%	-11.55%	-16.93%	8.57%	7.96%	8.24%	7.27%	1.85%	1.34%	0.05%	0.06%	4.78%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $132,424K ÷ $962,681K
= 13.76%

CONMED Corporation's return on equity (ROE) has shown fluctuations over the periods analyzed.

From March 31, 2020, to September 30, 2021, the ROE remained relatively low, ranging from 0.05% to 8.24%. During this period, the ROE experienced some improvement but was still below double-digit figures.

Subsequently, there was a significant decline in ROE for the next few quarters, with negative ROE values recorded from June 30, 2022, to March 31, 2023. This indicates that the company's net income was insufficient to cover its shareholders' equity, resulting in a negative return.

However, starting from June 30, 2023, CONMED Corporation managed to reverse this trend, showing a positive ROE of 11.32%. The positive momentum continued into the following quarters, with ROE reaching as high as 14.12% by September 30, 2024.

Overall, CONMED Corporation demonstrated a mix of positive and negative ROE values during the period under review. The company's ability to generate higher returns on its shareholders' equity in the latter part of the analysis period indicates improved profitability and efficiency in utilizing its shareholders' investments.